# Creatine Safety and Tolerability in Premanifest HD: PRECREST

> **NCT00592995** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 64 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** Creatine monohydrate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00592995
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2014-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00592995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00592995, "Creatine Safety and Tolerability in Premanifest HD: PRECREST". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00592995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*